Cortistatin (CST), a novel hormone originally described in the rat, mouse, and human cerebral cortex, displays structural and functional similarities to somatostatin (SRIF). CST binds to all five somatostatin receptors and, differently from SRIF, also binds to MrgX2, which has recently been identified as its specific receptor. Little is known about the distribution of CST and MrgX2 in peripheral non-tumour and neoplastic tissues. The aim of the present study was therefore to determine by immunohistochemistry and mRNA analysis (RT-PCR) the distribution of CST and MrgX2 in 56 human non-tumour and 108 tumour tissues, with special reference to neuroendocrine tissue types. Despite the high level of CST mRNA expression in non-tumour and tumour (both neuroendocrine and nonneuroendocrine) tissues, the presence of immunoreactive CST was confirmed in a subset of gastroenteropancreatic, parathyroid, and pituitary non-tumour cells only, and showed a predominantly focal pattern in most neuroendocrine tumours. Co-localization experiments in the gastroenteropancreatic system demonstrated that the normal CST-producing cells are δ cells, while in the adenohypophysis no preferential co-localization of CST with any of the pituitary hormones was observed. MrgX2 mRNA was variably detected in the hypothalamus, pituitary, thyroid, lung, gastroenteropancreatic tract, testis, and ovary, and was negative in the cerebral cortex, parathyroid, and adrenal, as well as in a variety of tumour types. Conversely, immunolocalization of MrgX2 protein was restricted to neurohypophysis and testis, whilst all tumours analysed were negative. A possible explanation for the discrepancy between RT-PCR and immunohistochemistry is that MrgX2 protein was widely detected in blood vessels, scattered lymphocytes, and gastrointestinal ganglia in both normal and neoplastic samples. The findings demonstrate a selective distribution of CST in normal and neoplastic neuroendocrine tissues, suggesting that CST might have a broader functional role than previously assumed, whereas possible autocrine/paracrine actions via its recently described specific receptor MrgX2 are restricted to selected tissues.
Introduction
Cortistatin (CST) is a 17-amino acid neuropeptide recently discovered in rat, mouse, and humans that exhibits strong structural homology to somatostatin (SRIF) [1] [2] [3] [4] . The human CST gene was mapped to chromosome 1p36.3-p36.2 and found to contain two exons separated by a 1 kb intron [3, 5] .
Two mature products, CST-17 and CST-29, are generated by a prohormone convertase, the former being equivalent to murine CST-14, a cyclic peptide that shares 11 of its 14 amino acid residues with SRIF-14, responsible for SRIF binding to its receptors [1, 2] .
CST-17 and CST-29 bind to all five SRIF receptors (subtypes [1] [2] [3] [4] [5] with an affinity comparable to that of SRIF-14 [6] . In addition, both CST-14 and CST-17, but not SRIF-14, are also able to bind the ghrelin receptor type 1a (growth hormone secretagogue receptor -GHS-R1a) [7] [8] [9] . SRIF receptors mediate multiple SRIF activities including neurotransmission, neuromodulation, regulation of endocrine and exocrine secretions, and also the inhibition of tumour growth [10, 11] . Since CST mediates several of its effects 
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via activation of SRIF receptors, it was assumed to share the same biological activities as SRIF. However, CST also exerts a number of distinct biological activities (increases slow wave sleep, reduces locomotor activity) and this evidence led to the existence of a specific CST receptor being postulated [1] .
Recently a novel receptor, named MrgX2 and belonging to a family of coding sequences related to the Mas1 oncogene, has been identified and found to possess a high affinity for CST-14 in vitro. MrgX2 has been identified in the small sensory neurons of the dorsal root ganglia (with a possible role in nociception) and in rare hippocampal neurons, but not in the cerebral cortex [12] , as opposed to CST, which is expressed by a distinct subset of gamma amino butyric acid (GABA)-containing cells in the cortex and hippocampus [13] .
In tissues other than the central nervous system, CST has been localized in the human endocrine pancreas [14] , a finding possibly related to the recently reported [9] capability of CST to inhibit basal insulin secretion (probably mediated via SRIF receptors), and in the immune system [15] .
Concerning MrgX2 distribution in peripheral tissues, weak immunohistochemical reactivity was originally reported in endothelial cells and the testis [12] , but no data are available on CST and MrgX2 distribution in other normal and neoplastic tissues to date. Since a possible role for CST in tumour growth control has been reported in thyroid [16] and liver [17] carcinoma cell lines, the aim of the present study was to analyse CST and MrgX2 distribution in a large series of human tissues and related tumours (with special reference to endocrine tumours), to create a map of tissues expressing this novel hormone and its target binding sites.
Materials and methods
Tissue samples
A total of 56 non-tumour autopsy or surgical samples included cerebral cortex (four cases), hypothalamus (three cases), pituitary gland (four cases), thyroid (five cases), parathyroid (two cases of hyperplasia), adrenal gland (two cases), lung (nine cases), stomach (six cases), ileum (four cases), colon (eight cases), pancreas (five cases), ovary (three cases), and testis (one case). Serial sections from formalin-fixed, paraffinembedded material were used for conventional histology, immunohistochemistry, and immunofluorescence studies. An adjacent fragment was snap-frozen and kept at −80
• C until it was processed for molecular analysis. In addition, a series of neuroendocrine tumours, for which both fresh frozen and paraffinembedded material was available in most cases, were also studied. These included 73 benign and malignant neuroendocrine tumours from the pancreas (32 cases), lung (five cases), parathyroid (four cases), thyroid (seven cases of medullary carcinoma), adrenal medulla (five cases), pituitary gland (two cases), skin (ten cases), and gastrointestinal tract (eight cases). The hormonal status of the neuroendocrine tumours analysed was confirmed by clinical syndromes, hormonal measurements, and immunohistochemical findings. Finally, a total of 35 non-neuroendocrine tumours from the pancreas (five ductal adenocarcinomas), lung (three adenocarcinomas and two squamous cell carcinomas), thyroid (three follicular adenomas, three follicular carcinomas, three papillary carcinomas, and two anaplastic carcinomas), gastrointestinal tract (12 adenocarcinomas), and testis (two seminomas) were also analysed. The study was performed according to the standards of the Institutional Ethical Committee and to the Helsinki Declaration of 1975 as revised in 1983. The Institutional Review Board of our hospital approved the study. All tissue samples were deidentified and anonymized by staff not involved in the study, according to published procedures [18] .
Immunohistochemistry (IHC)
A standard manual immunoperoxidase procedure for cortistatin-17 (CST-17) and MrgX2 was used on formalin-fixed and paraffin-embedded tissue sections after microwave heating and endogenous biotin activity blockade. CST immunostaining was performed using a commercial rabbit polyclonal antibody to human CST-17 (Phoenix Pharmaceutical, Belmont, CA, USA), diluted 1/10 000 and incubated for 1 h at room temperature. Rabbit polyclonal antibody to MrgX2 was purchased from LifeSpan (Seattle, WA, USA), diluted 1/750 and incubated overnight. The secondary antibody step, incubation with the streptavidin-peroxidase kit (Biogenex, San Ramon, CA, USA) and diaminobenzidine incubation, followed. For CST IHC reactions, further amplification with biotinylated tyramide (diluted 1/15; GenPoint kit, Dako, Glostrup, Denmark) and a second incubation with streptavidin were performed. Control experiments included the omission of the primary antibody in serial sections or, in the case of CST IHC, pre-absorption of the primary antibody with a 100-fold excess of CST-17 (Phoenix Pharmaceutical) or of SRIF-14 (Bachem Feinchemikalien, AG Bubendorf, Switzerland). Cerebral cortex or pancreatic islets [2, 14] and human testis [12] served as positive controls for CST and MrgX2, respectively.
Co-localization experiments
In double immunofluorescence co-localization experiments on the same slides of human pancreas and gastrointestinal tissue, the same antibody to CST (diluted 1/15) used for IHC, a mouse monoclonal antibody to insulin (diluted 1/40; Biogenex, clone HB125), or rabbit polyclonal antibodies to glucagon (pre-diluted; Biogenex) and SRIF (diluted 1/30; Dako) were employed. A FITC-labelled secondary anti-rabbit antibody (Sigma Aldrich, Steinheim, Germany) was used to reveal the CST immune reaction and TRITClabelled anti-mouse secondary antibody (Southern Biotech Associates, Inc, Birmingham, USA) was used to reveal insulin. Glucagon and SRIF-producing cells were revealed by an anti-rabbit biotinylated secondary antibody (diluted 1/50; Multilink kit, Biogenex) followed by a TRITC-avidin incubation step (Sigma Aldrich). Double immunofluorescence slides were analysed using an Olympus FV300 confocal microscope (Hamburg, Germany) equipped with a green helium neon (543 nm) laser, a blue argon (488 nm) laser, and FluoView 300 software. In double-label experiments, the two channels were scanned alternately, using only one laser and one detector at any given time to avoid cross-talk. Cells were imaged using a 60× oil immersion objective. In the case of pituitary tissue, CST (diluted 1/10 000), and rabbit polyclonal antibodies to prolactin and ACTH (both diluted 1/100; Biogenex), and GH (1/2000; Dako) were used in a double immunohistochemical procedure, by means of an immunoalkaline phosphatase (LSAB plus kit, Dako)/Fast red (Biogenex) reaction in sequence to the standard streptavidin-peroxidase kit. To avoid interactions between the two immunological procedures, a treatment with 0.01 N HCl at 37
• C, followed by prolonged washing, was performed after the first reaction, as previously described [19] .
Molecular analysis of CST and MrgX2 transcripts
The presence of CST and MrgX2 mRNA was investigated by means of RT-PCR and dot Southern blot analysis. Total RNA extraction, cDNA transcription, and PCR amplification of the housekeeping gene (β 2 microglobulin) were performed as described elsewhere [20] . CST primer sequences and PCR conditions have been reported previously [14] . Primers and probes used to identify the specific MrgX2 mRNA were selected according to recently published sequences [12] . Cranial nerve ganglion and cerebral cortex mRNA extracts served as positive controls for MrgX2 and CST, respectively. Negative controls included omission of reverse transcriptase enzyme from the reverse mixture and of cDNA from the PCR mixture.
The SRIF receptors and GHS-R1a status of most cases of the current neuroendocrine tumour series have been reported previously [20] [21] [22] [23] [24] . Additional RT-PCR experiments for SRIF receptors and GHS-R1a were also performed in selected cases, with special reference to non-tumour and neoplastic parathyroid tissue, according to previously published protocols [20, 21] .
For both CST and MrgX2 experiments, dot Southern blot analysis was performed to test the specificity of the RT-PCR product further, as previously reported for CST [14] .
Results
Cortistatin mRNA and protein expression in non-tumour tissues CST mRNA and protein expression in non-tumour tissues, as revealed by RT-PCR and immunohistochemistry, is summarized in Table 1 .
Concerning RT-PCR data, tissue samples from the cerebral cortex, hypothalamus, pituitary gland, thyroid, parathyroid, adrenal gland, ileum, and testis were positive in all cases investigated. Large intestine and pancreas were positive in the majority of cases, whereas a lower rate of expression was detected in the lung, stomach, and ovary.
Immunolocalization of CST protein was detected in the cytoplasm of neuronal cells of the cerebral cortex and hypothalamus, as well as in neuroendocrine Despite positive RT-PCR results, no immunoreactivity for CST was found in the lung, ovary, thyroid, testis, and adrenal, neither in neuroendocrine nor in non-neuroendocrine cell types. Interestingly, CST peptide was diffusely present in chief cells of the parathyroid gland, oxyphilic cells being weakly immunoreactive (Figure 3) . No SRIF-immunoreactive cells were detected in parathyroid tissue samples. In order to clarify the potential autocrine/paracrine role of CST in the parathyroid gland, the presence of SRIF receptor subtypes and MrgX2 (see also below) and GHS-R1a mRNAs in non-tumour (hyperplastic) and neoplastic samples was tested. Neither non-neoplastic nor neoplastic tissues showed MrgX2 and GHS-R mRNA expression, while SRIF receptor subtypes 1 and 2 (and 3 in a single case of parathyroid carcinoma) mRNA signal was demonstrated.
In control experiments, no immunoreactivity was found in parallel sections stained omitting the primary antibody or in pre-absorption experiments with an excess of CST-17 peptide, whereas CST reactivity was preserved after pre-absorption with an excess of SRIF-14.
MrgX2 mRNA and protein expression in non-tumour tissues
MrgX2 mRNA was distributed heterogeneously among different non-tumour tissues (see Table 1 ). No specific MrgX2 mRNA was demonstrated in the cerebral cortex, parathyroid or adrenal gland. Variable amounts of MrgX2 transcripts were demonstrated in all other tissues, the hypothalamus (3/3 cases), the thyroid (3/5 cases), and the pancreas (3/5 cases) being the most positive. Tissue localization analysis by immunohistochemistry (see Table 1 ) detected MrgX2 protein in scattered neurons of the neurohypophysis (adjacent to pituicytes in a single case) and in testicular tubules. No neuroendocrine cells in any site showed MrgX2 immunoreactivity. Conversely, MrgX2 protein was localized in blood vessels (endothelia), gastrointestinal ganglion cells, and scattered lymphocytes present in most tissues investigated (Figure 4) .
Cortistatin mRNA and peptide expression in neuroendocrine and non-neuroendocrine tumours CST peptide and mRNA expression data in neuroendocrine tumours are summarized in Table 2 . Specific CST mRNA was detected in all phaeochromocytomas, parathyroid adenomas, and neuroendocrine tumours of the lung, as well as in non-functioning pancreatic endocrine tumours. A specific signal was found in the majority of the other neuroendocrine tumours tested, namely neuroendocrine tumours of the gastrointestinal tract; functioning neuroendocrine tumours of the pancreas (Figure 5 ), where no specific association was observed in CST-positive tumours with respect to hormone production; medullary thyroid carcinomas; parathyroid carcinomas; and Merkel cell carcinomas.
The majority of the neuroendocrine tumours that contained CST mRNA by RT-PCR were also CSTpositive by immunohistochemistry, with the exception of parathyroid adenoma and Merkel cell carcinoma, which showed no immunoreactivity. The immunohistochemical pattern of CST was granular cytoplasmic and the staining ranged from 5-10% (the predominant feature) to 90% (in a minority of cases) of tumour cells, irrespective of the histological pattern or the tissue of origin ( Figure 6 ). No correlation was observed between CST expression and tumour behaviour.
Concerning putative endocrine precursor lesions, in two CST-negative medullary thyroid carcinoma cases (one associated with MEN2A syndrome and one sporadic), peritumoural C-cell hyperplasia was also negative by CST immunohistochemistry. Moreover, in a case of gastric carcinoid, both the tumour and the foci of adjacent nodular neuroendocrine cell hyperplasia were CST-immunoreactive ( Figure 6 ). In the non-neuroendocrine tumour group, a weak mRNA signal was present in most cases, particularly in adenocarcinomas of the lung, stomach, and colon, and in follicular tumours of the thyroid. By contrast, CST immunohistochemistry failed to demonstrate immunoreactive cells in any of the nonneuroendocrine tumours.
MrgX2 mRNA and protein expression in neuroendocrine tumours
MrgX2 mRNA and protein expression was analysed in 24 selected neuroendocrine tumour samples (see Table 2 ) that showed immunoreactivity for CST, to correlate the presence of the hormone product with its putative receptor. MrgX2 mRNA was detected in 8/24 tumours, generally with a weak signal. As observed in normal tissues (see above), MrgX2 protein localization was restricted to peritumoural blood vessels, ganglia, and lymphocytes, whereas the neoplastic component was negative in all 24 neuroendocrine tumour samples investigated, as well as in 12 control nonneuroendocrine tumours (three lung, three pancreatic, and three gastrointestinal adenocarcinomas; two seminomas; and one papillary thyroid carcinoma).
Discussion
In the present study, we have demonstrated that endocrine cells of the gastrointestinal tract, the pancreas, the pituitary, and parathyroid glands produce CST. Co-localization experiments showed that in both gastrointestinal tract and endocrine pancreas, the majority of neuroendocrine CST-producing cells coexpress SRIF peptide, thus corresponding to δ cells. A slightly decreasing density of CST-positive cells was observed from the proximal to the distal gastrointestinal tract, in agreement with the distribution of δ cells [25] . The biological significance of dual expression in δ cells of CST and SRIF, which share both similarities (all SRIF receptor-mediated actions) and differences (CST actions mediated by non-SRIF receptors), remains unclear. The expression of SRIF receptors in neuroendocrine cells of the gastroenteropancreatic system has been demonstrated previously [20] and suggests puzzling circuits of autocrine/paracrine/endocrine regulation that would be exerted by either SRIF or CST, as demonstrated by insulin secretion and glucose metabolism at the pancreatic level [26] . However, as already mentioned, at variance with SRIF, CST also binds to the ghrelin receptor GHSR1a that is widely expressed in the gastroenteropancreatic tract, where it mediates endocrine and nonendocrine actions. This would predict a functional interplay between the ghrelin system and CST, but not SRIF. Moreover, the relevance of functional differences between CST and SRIF has been emphasized by the recent cloning of MrgX2, the putative CSTspecific receptor that is recognized by CST but not SRIF [12] . This discovery requires detailed mapping of its distribution in different tissues in order to define its potential biological properties and CST targets better. Here, we have demonstrated that although MrgX2 mRNA is widely expressed in peripheral non-tumour and tumour tissues, its protein expression is selectively restricted to testicular tubules (as also reported in the original description by Robas et al [12] ), to the widespread vascular and nerve structures, and to reactive lymphocytes. This latter observation deserves further studies on the role of the CST/MrgX2 axis in the immune system, since CST expression has also been reported in lymphocytes and other immune cell types [15] .
A peculiar and unexpected finding was the presence of CST peptide (but not SRIF) in parathyroid chief cells. The possibility that the parathyroid gland could produce peptide hormones other than parathormone, namely calcitonin, has been recently described [27] . The presence of SRIF receptors (particularly subtype 2) correlates with the reported positivity of some parathyroid tumours on octreotide scintigraphy [28] , although the absence of any biological effect of octreotide on parathormone secretion has been reported by others [29, 30] . In any case, since neither MrgX2 nor GHS-R1a was found in normal and neoplastic parathyroid tissues, the possibility that CST plays a role in regulating parathyroid function via SRIF receptor subtypes (1-3), in either physiological or pathological conditions, should be considered.
With regard to tumours, scattered CST-immunoreactive cells (but not the corresponding MrgX2 receptor) were found in the majority of gastroenteropancreatic neuroendocrine tumours. No preferential association of CST with tumour behaviour or specific hormone secretion was observed. The possible existence of CST-secreting neuroendocrine tumours leading to chronic CST hypersecretion should be validated by detailed clinical and biochemical monitoring of hormonal parameters. Limited evidence for the role of CST in tumour growth control has already been reported [16, 17] . Since all immunohistochemically CST-positive tumours did not contain MrgX2 protein, whereas the expression of SRIF receptors (particularly SRIF receptors 2, 3, and 5) and/or GHSR-1a had previously been detected [20] [21] [22] [23] [24] in all samples (at either protein or mRNA level), the actions of CST were probably mediated by pathways other than CST/MrgX2 in the tumours investigated.
Concerning CST and MrgX2 mRNA analysis, our results are in agreement with recently published quantitative RT-PCR data showing widespread CST mRNA expression in peripheral tissues [31] . However, as observed, for example, for MrgX2 protein localization in blood vessels, pure mRNA data, especially when using very sensitive techniques such as quantitative PCR, should be interpreted carefully, and cannot stand alone without comparative analysis with tissue localization methods (immunohistochemistry or in situ hybridization). With regard to this, our heterogeneous MrgX2 mRNA data on normal tissues may be related either to different detection thresholds in different samples (due to different amounts of interspersed positive cells -ie endothelia, lymphocytes or ganglion cells) or possibly to unrecognized mechanisms of modulation of the expression of the receptor.
In conclusion, we have demonstrated that, firstly, CST is produced by a subset of normal neuroendocrine cells, from the pancreas, gastrointestinal tract, pituitary, and parathyroid; secondly, in the gastroenteropancreatic system these cells appear to be predominantly δ cells; thirdly, the CST receptor, MrgX2, is selectively expressed by neurohypophyseal neurones, testis, blood vessels, reactive lymphocytes, and gastrointestinal ganglia; and fourthly, a consistent number of neuroendocrine tumours from different sites express CST focally, but not its receptor MrgX2: possible autocrine/paracrine CST actions in neoplastic conditions could therefore be mediated by SRIF or ghrelin receptors.
